Comparison of Two brands of Methylphenidate (Stimdate® vs. Ritalin®) in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial

AUTHORS

Naser Khodadust 1 , * , Amir-Hossein Jalali 2 , Masoud Ahmadzad-Asl 3 , Noushin Khademolreza 4 , Elham Shirazi 2

1 Mental Health Research Center, Tehran Psychiatric Institute, Tehran University of Medical Sciences and Health Services, Tehran, Iran. Address: No.1 Mansouri St, Niyayesh St, Sattarkhan Ave, Tehran, Iran

2 Assistant Professor of Psychiatry, Mental Health Research Center, Tehran Psychiatric Institute, Tehran University of Medical Sciences and Health Services, Tehran, Iran

3 Resident of Psychiatry, Mental Health Research Center, Tehran Psychiatric Institute, Tehran University of Medical Sciences and Health Services, Tehran, Iran

4 Psychiatrist, Mental Health Research Center, Tehran Psychiatric Institute, Tehran University of Medical Sciences and Health Services, Tehran, Iran

How to Cite: Khodadust N, Jalali A, Ahmadzad-Asl M, Khademolreza N, Shirazi E. Comparison of Two brands of Methylphenidate (Stimdate® vs. Ritalin®) in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial, Iran J Psychiatry Behav Sci. 2012 ; 6(1):26-32.

ARTICLE INFORMATION

Iranian Journal of Psychiatry and Behavioral Sciences: 6 (1); 26-32
Published Online: June 30, 2012
Article Type: Original Article
Received: September 24, 2011
Revised: December 02, 2011
Accepted: January 31, 2012

Crossmark

CHEKING

READ FULL TEXT
Abstract

Objective: To compare the effectiveness and safety of the methylphenidate produced in Iran (StimdateÆ) with its original brand (RitalinÆ) in children with Attention deficit hyperactivity disorder (ADHD). Methods: In this double-blinded randomized clinical trial, 30 patients with ADHD who were 6 to 16 years old, were divided into two groups: 15 in StimdateÆ and 15 in RitalinÆ group. The two groups were compared for side effects profile, Connerís Parentís Rating Scale-Persion version (CPRS-R), Child Symptom Inventory-4 (CSI-4), Clinical Global Impressions (CGI), and Childrenís Global Assessment Scale (CGAS), at baseline and at the 4 th and 6 th weeks. Results: The subjects showed significant decreases in the CPRS-Rand CSI-4 scores and significant increase of CGAS scores during the follow-up, but there were no significant difference between StimdateÆ and RitalinÆ group, regarding the pattern of changes observed. The mean therapeutic dose and the number of side effects were not significantly different between the two studied groups.

Conclusions: Both StimdateÆ and RitalinÆ had comparable clinical efficacy and safety in children with ADHD.

Declaration of interest: None.

Clinical Trial Registration-URL: http:// #_> www.irct.ir. Unique identifier: IRCT201106306923N1. Citation: Comparison of two brands of methylphenidate (StimdateÆ vs. Ritalin Æ ) in children and adolescents with attention deficit hyperactivity disorder: a double-blind, randomized clinical trial. Khodadust N.Jalali AH, Ahmadzad-Asl M, Khademol N, Shirazi E .Iran J Psychiatry Behave Sci 2012; 6(1): 26-32.

Keywords

ADHD Ritalin Side effects Stimdate Therapeutic effect

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Fulltext

Full text is available in the PDF.

References

  • 1.

    References are available in the PDF.

  • COMMENTS

    LEAVE A COMMENT HERE: